S&P 500   3,327.68 (+0.00%)
DOW   27,222.04 (+0.08%)
QQQ   272.23 (+0.44%)
AAPL   447.94 (+1.75%)
MSFT   213.32 (+0.18%)
FB   262.16 (+5.23%)
GOOGL   1,495.66 (+1.12%)
AMZN   3,209.00 (+0.12%)
NVDA   449.52 (-0.43%)
CGC   18.14 (-5.57%)
BABA   262.29 (-0.99%)
TSLA   1,494.54 (+0.64%)
MU   48.49 (-5.02%)
GE   6.29 (-1.72%)
AMD   86.02 (+0.83%)
T   29.77 (-0.30%)
F   6.95 (-0.14%)
ACB   10.28 (-4.01%)
GILD   69.21 (+0.30%)
NFLX   504.54 (+0.48%)
DIS   129.61 (+1.57%)
BAC   25.40 (+0.04%)
BA   172.13 (-1.23%)
S&P 500   3,327.68 (+0.00%)
DOW   27,222.04 (+0.08%)
QQQ   272.23 (+0.44%)
AAPL   447.94 (+1.75%)
MSFT   213.32 (+0.18%)
FB   262.16 (+5.23%)
GOOGL   1,495.66 (+1.12%)
AMZN   3,209.00 (+0.12%)
NVDA   449.52 (-0.43%)
CGC   18.14 (-5.57%)
BABA   262.29 (-0.99%)
TSLA   1,494.54 (+0.64%)
MU   48.49 (-5.02%)
GE   6.29 (-1.72%)
AMD   86.02 (+0.83%)
T   29.77 (-0.30%)
F   6.95 (-0.14%)
ACB   10.28 (-4.01%)
GILD   69.21 (+0.30%)
NFLX   504.54 (+0.48%)
DIS   129.61 (+1.57%)
BAC   25.40 (+0.04%)
BA   172.13 (-1.23%)
S&P 500   3,327.68 (+0.00%)
DOW   27,222.04 (+0.08%)
QQQ   272.23 (+0.44%)
AAPL   447.94 (+1.75%)
MSFT   213.32 (+0.18%)
FB   262.16 (+5.23%)
GOOGL   1,495.66 (+1.12%)
AMZN   3,209.00 (+0.12%)
NVDA   449.52 (-0.43%)
CGC   18.14 (-5.57%)
BABA   262.29 (-0.99%)
TSLA   1,494.54 (+0.64%)
MU   48.49 (-5.02%)
GE   6.29 (-1.72%)
AMD   86.02 (+0.83%)
T   29.77 (-0.30%)
F   6.95 (-0.14%)
ACB   10.28 (-4.01%)
GILD   69.21 (+0.30%)
NFLX   504.54 (+0.48%)
DIS   129.61 (+1.57%)
BAC   25.40 (+0.04%)
BA   172.13 (-1.23%)
S&P 500   3,327.68 (+0.00%)
DOW   27,222.04 (+0.08%)
QQQ   272.23 (+0.44%)
AAPL   447.94 (+1.75%)
MSFT   213.32 (+0.18%)
FB   262.16 (+5.23%)
GOOGL   1,495.66 (+1.12%)
AMZN   3,209.00 (+0.12%)
NVDA   449.52 (-0.43%)
CGC   18.14 (-5.57%)
BABA   262.29 (-0.99%)
TSLA   1,494.54 (+0.64%)
MU   48.49 (-5.02%)
GE   6.29 (-1.72%)
AMD   86.02 (+0.83%)
T   29.77 (-0.30%)
F   6.95 (-0.14%)
ACB   10.28 (-4.01%)
GILD   69.21 (+0.30%)
NFLX   504.54 (+0.48%)
DIS   129.61 (+1.57%)
BAC   25.40 (+0.04%)
BA   172.13 (-1.23%)
Log in

NASDAQ:ACRSAclaris Therapeutics Stock Price, Forecast & News

$2.10
-0.05 (-2.33 %)
(As of 08/6/2020 12:38 PM ET)
Add
Compare
Today's Range
$2.10
Now: $2.10
$2.17
50-Day Range
$1.45
MA: $1.89
$2.45
52-Week Range
$0.70
Now: $2.10
$3.34
Volume2,877 shs
Average Volume926,990 shs
Market Capitalization$87.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.3
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 MK-2 pathway oral inhibitor for the treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, cryopyrin-associated periodic syndrome, and pyoderma gangrenosum; ATI-1777 JAK1/JAK3 soft topical inhibitor for atopic dermatitis, vitiligo, and alopecia areata; ITK/JAK3 soft topical and oral inhibitors to treat psoriasis and inflammatory diseases; MK-2 pathway oral inhibitor for oncology; and ITK-JAK3 oral gut-restricted inhibitor for ulcerative colitis/Crohn's disease. Further, it provides contract research laboratory services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
Read More
Aclaris Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.52 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRS
CUSIPN/A
Phone484-324-7933

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.23 million
Book Value$1.69 per share

Profitability

Net Income$-161,350,000.00
Net Margins-1,490.64%

Miscellaneous

Employees169
Market Cap$87.93 million
Next Earnings Date8/13/2020 (Estimated)
OptionableOptionable
$2.10
-0.05 (-2.33 %)
(As of 08/6/2020 12:38 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ACRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Aclaris Therapeutics (NASDAQ:ACRS) Frequently Asked Questions

How has Aclaris Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Aclaris Therapeutics' stock was trading at $1.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ACRS stock has increased by 98.1% and is now trading at $2.10.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Aclaris Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Aclaris Therapeutics
.

When is Aclaris Therapeutics' next earnings date?

Aclaris Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020.
View our earnings forecast for Aclaris Therapeutics
.

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics Inc (NASDAQ:ACRS) issued its earnings results on Thursday, May, 7th. The biotechnology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $0.01 by $0.38. The biotechnology company earned $1.41 million during the quarter, compared to analysts' expectations of $1.27 million. Aclaris Therapeutics had a negative return on equity of 99.67% and a negative net margin of 1,490.64%.
View Aclaris Therapeutics' earnings history
.

What price target have analysts set for ACRS?

4 analysts have issued 12 month price objectives for Aclaris Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Aclaris Therapeutics' stock price to reach $5.00 in the next year. This suggests a possible upside of 138.1% from the stock's current price.
View analysts' price targets for Aclaris Therapeutics
.

Has Aclaris Therapeutics been receiving favorable news coverage?

Media coverage about ACRS stock has trended very negative on Thursday, InfoTrie reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aclaris Therapeutics earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Aclaris Therapeutics
.

Are investors shorting Aclaris Therapeutics?

Aclaris Therapeutics saw a decline in short interest during the month of July. As of July 31st, there was short interest totaling 1,240,000 shares, a decline of 9.5% from the July 15th total of 1,370,000 shares. Based on an average daily volume of 690,800 shares, the days-to-cover ratio is currently 1.8 days. Approximately 4.0% of the shares of the company are sold short.
View Aclaris Therapeutics' Current Options Chain
.

Who are some of Aclaris Therapeutics' key competitors?

What other stocks do shareholders of Aclaris Therapeutics own?

Who are Aclaris Therapeutics' key executives?

Aclaris Therapeutics' management team includes the following people:
  • Dr. Neal S. Walker D.O., Co-Founder, CEO, Pres & Director (Age 49)
  • Mr. Christopher V. Powala, Co-Founder and Chief Regulatory & Devel. Officer (Age 60)
  • Dr. Stuart D. Shanler, Co-Founder & Chief Scientific Officer (Age 58)
  • Mr. Frank Ruffo, Co-Founder & CFO (Age 53)
  • Ms. Kamil Ali-Jackson J.D., Co-Founder, Chief Legal Officer, Chief Compliance Officer & Sec. (Age 60)

What is Aclaris Therapeutics' stock symbol?

Aclaris Therapeutics trades on the NASDAQ under the ticker symbol "ACRS."

Who are Aclaris Therapeutics' major shareholders?

Aclaris Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include WINTON GROUP Ltd (0.11%). Company insiders that own Aclaris Therapeutics stock include Anand Mehra, James E Flynn and Stephen A Tullman.
View institutional ownership trends for Aclaris Therapeutics
.

Which major investors are selling Aclaris Therapeutics stock?

ACRS stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd.
View insider buying and selling activity for Aclaris Therapeutics
.

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Aclaris Therapeutics' stock price today?

One share of ACRS stock can currently be purchased for approximately $2.10.

How big of a company is Aclaris Therapeutics?

Aclaris Therapeutics has a market capitalization of $87.93 million and generates $4.23 million in revenue each year. The biotechnology company earns $-161,350,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. Aclaris Therapeutics employs 169 workers across the globe.

What is Aclaris Therapeutics' official website?

The official website for Aclaris Therapeutics is www.aclaristx.com.

How can I contact Aclaris Therapeutics?

Aclaris Therapeutics' mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company can be reached via phone at 484-324-7933 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.